Emergent Biosolutions
EBS
272 hedge funds and large institutions have $2.21B invested in Emergent Biosolutions in 2018 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 98 increasing their positions, 79 reducing their positions, and 17 closing their positions.
224% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 17
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 79
18% more capital invested
Capital invested by funds: $1.88B → $2.21B (+$333M)
14% more funds holding
Funds holding: 238 → 272 (+34)
12.49% less ownership
Funds ownership: 97.58% → 85.09% (-12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.9M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
+$17M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.9M |
| 4 |
Renaissance Technologies
New York
|
+$14.1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$32.8M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
-$26.5M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$21.9M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$12.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$9.15M |
EBS Hedge Fund Activity: Q1 2018 in Review
272 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2018, worth a combined $2.21B — up 18% from $1.88B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new EBS positions and 17 closed out — a net gain of 38 holders — while 98 added to existing stakes and 79 trimmed.
The largest buyer was Vanguard Group, adding an estimated $27.9M. The largest seller was Manulife (Manufacturers Life Insurance), cutting an estimated $32.8M.
- 272 institutional investors held Emergent Biosolutions (EBS) as of Q1 2018, up from 238 in Q4 2017.
- Funds reported $2.21B of Emergent Biosolutions stock for Q1 2018, up 18% quarter-over-quarter.
- 55 funds opened new Emergent Biosolutions positions in Q1 2018 and 17 closed out, a net change of +38 holders.
- The largest Emergent Biosolutions buyer in Q1 2018 was Vanguard Group, an estimated $27.9M added.
- The largest Emergent Biosolutions seller in Q1 2018 was Manulife (Manufacturers Life Insurance), an estimated $32.8M sold.
Based on aggregated 13F filings for Q1 2018.